Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

Peer Review reports

Original Submission
28 Dec 2018	Submitted	Original manuscript
10 Jan 2019	Reviewed	Reviewer Report - Justin Brown
10 Jan 2019	Reviewed	Reviewer Report - George Kelley
20 Feb 2019	Author responded	Author comments - Xiaoying Sun
Resubmission - Version 2
20 Feb 2019	Submitted	Manuscript version 2
1 Mar 2019	Reviewed	Reviewer Report - Justin Brown
2 May 2019	Reviewed	Reviewer Report - Reviewer 2
8 May 2019	Author responded	Author comments - Xiaoying Sun
Resubmission - Version 3
8 May 2019	Submitted	Manuscript version 3
Publishing
10 May 2019	Editorially accepted
10 Jun 2019	Article published	10.1186/s12885-019-5701-6

Back to article page